Astellas Oncology is committed to elevating the standard of cancer care. We focus on developing innovative, targeted therapies for hard-to-treat cancers with limited treatment options, which is where we see the greatest opportunity to help people living with cancer.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.
Flatiron Health is a healthtech company that marries clinical and data science to improve outcomes for cancer patients today and tomorrow. We translate patient experiences into real-world evidence to advance research and inform policy. Flatiron HC isn’t just the leading cancer-specific EHR. It’s the platform for a better patient experience, a healthier practice and smarter research. We help oncologists provide better care for their patients. Together, we can outsmart cancer. Flatiron Health is an independent affiliate of the Roche Group.
G1 Therapeutics, Inc., is a commercial-stage biopharmaceutical company focused on the discovery, development, and delivery of next-generation therapies. The company’s first commercially available product, COSELA™ (trilaciclib), was recently approved by the US Food and Drug Administration. G1 Therapeutics, Inc., is based in Research Triangle Park, North Carolina. For additional information, please visit www.g1therapeutics.com.
For more than 40 years, we've been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. For more information about Genentech visit gene.com.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to pursuing scientific invention to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at: www.janssen.com.
Follow us at: www.twitter.com/JanssenGlobal.
About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com
At Sanofi Genzyme we help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive’s goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
Amgen Oncology is committed to the relentless pursuit of breakthroughs for cancer patients and their families. Our portfolio features many first-in-class oncology/hematology medicines and innovative
therapies for difficult-to-treat cancers.
Athenex Oncology is a team of scientists, investigators, and innovators driven by the patients we serve. Our robust investigational pipeline of novel small molecule, biologic, and cellular therapies is focused on both improving outcomes and the cancer experience. Visit AthenexOncology.com
Social Media Profiles:
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics.
Cardinal Health Specialty Solutions empowers community oncology practices to navigate the future of oncology care. Working in close collaboration with each practice, we develop and implement a clear
roadmap to meet pressing challenges in a new era. With expert insights, responsive tools and committed support, we enable our customers to deliver high-quality, cost-efficient care so they can future-proof their practices. For oncologists, these services are delivered through VitalSource™ GPO and Navista™ TS. Learn more at cardinalhealth.com/vitalsourcegpo or cardinalhealth.com/navista
Founded in 1992 in Germany, MorphoSys is dedicated to making innovative biopharmaceuticals to help patients suffering from serious diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development.
MorphoSys is headquartered in Planegg, Germany. In 2019, the US head office was established in Boston.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at www.novartis.com.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.
As the largest oncology-specific GPO and physician service organization, ION Solutions is the preferred strategic partner for community oncology practices nationwide.
With over 20 years of experience, you can rely on us for more than GPO contracts. In addition to giving you access to the most advanced therapies at competitive contract rates, our experts take pride in helping member practices tap the potential within their business. Whether you're interested in uncovering new clinical and operational efficiencies, opening new lines of revenue, or need support navigating the transition to value-based reimbursement—ION Solutions will be there to help you, every step of the way.
In 1998, Oncology Supply became the exclusive distributor for ION Solutions. For more than 40 years, they have stood side by side with community oncology practices across the United States. With access to the entire AmerisourceBergen network, they improve product access, increase supply chain efficiency and work diligently to support practices in enhancing patient care.
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. For additional information, please visit www.coherus.com.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach in oncology focuses on oncogenic pathways, immuno-oncology, and DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and partner on exciting asset programs and integrated innovations. We aim to deliver personalized treatment options that may potentially transform cancer care.
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. To ensure you have the latest clinical data, including links to our pivotal trial publications, and important product information, visit our website.
Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. We seek to discover innovative therapies to improve standards of care and strive to help our patients rediscover the Magic of Normal.
Taiho Oncology is a different kind of pharmaceutical company. We have deep roots and unmatched corporate agility that enable us to fulfill our purpose – making treatments for Oncology.
For almost two decades, Taiho Oncology has served as a clinical organization, where people are at the center of everything we do. Together, we work urgently to discover and develop treatments that address today’s unmet patient needs and apply the science behind them.
As the field of Oncology treatment evolves, we evolve with it. Technology, dedicated investigators, and established facilities—these vast resources empower us. It’s our work; it’s our passion; it’s our legacy.
At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialization to meet the needs of the cancer community, optimizing our ability to bring potentially transformative medicines to patients. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches, enable us to bring novel medicines to patients worldwide.
For more information, visit www.takedaoncology.com.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
BeyondSpring Pharmaceuticals is a global biopharmaceutical company with headquarters in New York City is focused on developing innovative cancer therapies to improve clinical outcomes. BeyondSpring is committed to raising the standard of care in cancer with our first-in-class lead asset plinabulin, a selective immunomodulating microtubule - binding agent (SIMBA), which is being developed as a “pipeline in a drug.” Plinabulin has received Breakthrough status and Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia, a potentially life-threatening side
effect of chemotherapy, with a PDUFA date of November 30, 2021 in the U.S.
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.
Epizyme, Inc. is a fully integrated biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through transformative epigenetic medicines. In addition to a robust research and discovery pipeline, Epizyme has one commercial oncology product and is exploring the treatment potential of this therapy in investigational clinical trials focused on other conditions. By focusing on the genetic drivers of disease, Epizyme works to match new medicines with the patients who need them.
For more information, visit www.epizyme.com.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. For more information, visit www.foundationmedicine.com.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.
Integra Connect delivers a comprehensive, integrated suite of cloud-based technologies and services that enable oncology groups to optimize clinical and financial performance as reimbursement shifts to value-based models. Connected by the IntegraCloud platform, the company’s precision oncology focus and core applications span advanced analytics; registry and regulatory reporting; specialty-specific EHR; practice management; revenue cycle management to service specialty care with a primary focus on urology and radiation oncology. All are designed to help community oncology practices transform operationally in adherence with complex regulations, including MACRA program requirements.
Company social media:
Pharmacosmos Therapeutics Inc. is a U.S. specialty pharmaceutical company dedicated to providing patient care through the commercialization of Monoferric® (ferric der isomaltose) injection and through exceptional resources to support this treatment. We are the U.S. affiliate of the Denmark-based Pharmacosmos Group.
Please visit us at www.monoferric.com to learn more.